Inventor: Jonaiu Na Signature: Date (Optional): Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form.

(Currently Amended) The apparatus of claim +41§., further comprising a drive shaft coupling the motor to the at least one needle wherein each of the plurality of restorably deflectable electrical contacts includes a depressible pin.

The apparatus 10, 320, 360,360,400,460 may be employed to apply cosmetics, medications and/or other actives directly to the skin and maintain their presence long-term while using LED or other actinic light to increase their effect on the cells and tissue in the body.

[0059] Chemicals 22A may include cosmetics, medications and other actives appropriate for dermalogical cells including AHA's (alpha hydroxy acid), natural oils, aloe vera compounds, collagen boosters, bt, chitosan, daeses, endorphins, photodynamic drugs (PDT) like (Photofrin or ALA), vitamins A, C E or others, kojic acid, retinols or other exfoliant, salicylic acid, anti oxidants or other youth boosters and anti aging cosmetic or medications, antiseptic, antibiotics, anti-cancer agents, aroma therapy agents, fruit and vegetable extracts, anti-inflammatory agents, pain relievers, hormones, depilatories, and others, but the scope of this invention is not limited to these alone but can include any helpful medication, herbal formula or active compound for the skin and/or other tissues.

As noted the DTA 900 SGC 911 RFSG 91 lA, NDMC 91 lB, and PSG 911 C may enable a user or clinician to select a variety of operational parameters to deliver a desired combination of electrical, light (photonic), and mechanical (needle) therapy to dermalogical tissue.

The multiple conductive pathways can be selected electroni cally via a controllable Switching device or manually by rotational, lateral or longitudinal movement of the imped ance array within the target Volume.

Also, apparatus 10 can also have Sensors 22 disposed along elongated member 12 and other locations outside of the target tissue Site for measurement and determination of the total impedance acroSS the full electrical circuit between the terminals of power supply 20 (i.e. through the patient's body and into the ground pad).

In various embodiments sensor array 22a and/or member plurality 18pl can be configured to define a variety of shapes for Sample Volumes 5sv including, but not limited to, a hemisphere, a Sphere, an oval, a cone, pyramidal, a polyhedron or a tetrahedron.

The generation and display of the impedance locus 5li (in 2-D or 3-D) can be configured to provide the medical practitioner an easily discernable visual cue as to the location, Size or movement of the ablation, tumor or other Selected tissue Volume.

In use, the infusion of the target tissue Site with conductivity enhancing Solution provides two important benefits: (i) faster ablation times; (ii) the creation of larger lesions; and (iii) reduced incidence of impedance related shut downs of the RF power supply.

Cynosure develops, manufactures, and distributes products for use in numerous medical and aesthetic applications, including hair removal, skin revitalization, scar reduction, gynecological health, body contouring, and more.

In an attempt to overcome the USPTO’s rejections, Na and Richman further falsely stated that “the Manstein reference does not teach applying a high frequency Alternating Current signal to bipolar electrodes.” Id., Response Under 37 CFR 1.111 (Oct. 18, 2015) at 9.

Despite Na and Richman’s statements to the contrary, Manstein in fact teaches, suggests, and describes, in a single embodiment, the application of high frequency AC signals to a plurality of electrodes operating in a bipolar mode.

Both Na and Richman had been aware of the fact that an RF signal is an oscillating current at least since 2008 when they submitted to the Korean Patent Office the ’052 Application, which disclosed that “the high- frequency, such as radio waves, are basically alternating current.”

Inequitable Conduct Claim 7 (Infection Unenforceability) The ’836, ’379, ’444, ’536, ’774, and ’812 Patents are directed to respective features of the same dermatological devices, share the same inventors and prosecuting attorney, have been licensed together (see, e.g., Complaint, Ex. 69), and are asserted together in the present ITC proceeding and related district court litigations.

Jul 09 – October 2017 Jan 2005 – April 2009 Chief Executive Officer & Director - Ventracor - Sydney Australia, USA and Europe An Australian Public Company developing and commercializing an implantable blood pump, the VentrAssist left ventricular assist device as therapy for patients in end stage heart failure.

1999-2004 Chief Executive Officer, Board Chairman - CardioComm Solutions, Inc. - Victoria BC, Canada A public software development company with products for management of real time ECG and patient data.

1989-1991 VP Tachycardia Global project management function, with responsibility for coordination of product development, clinical trial, regulatory strategy, and market launch for the emerging implantable cardioverter defibrillator (ICD) business.

Executive Chairman – CenSyn Inc. (Irvine, California) May 2020 – April 2022 An early stage medical device company developing and commercializing an “EEG Pen” to provide quick, efficient and accessible hand-held electroencephalogram (EEG) to monitor brain health during suspected neurological emergencies.

Re- engaged in early 2024 to provide a declaration in support of POPR in IPR2024-00383, Staff Petition for relief (“SPR”) I-2018-00036 dated March 28th, 2023 brought by the Bureau of Securities Regulation for the Secretary of State of New Hampshire against Advent Medical Products alleging misrepresentation of information in solicitations for funding.

I have here the time, and I guess 7 what I need to know also is how you made out in terms of 8 carving up another three hours, if I go that direction, 9 which, as you know, it sounds like I'm going in that 10 direction, and a revision to the original calculations 11 that -- well, the ones that you gave me on Monday to account 12 for, again, translation and so forth.

MR. WHEELER: Your Honor, I hate to interject, 14 but there is one item of business that impacts the time that 15 I'd like to announce to the Court before that, and that is 16 that Complainant has reached a settlement with respect to 17 some additional Respondents.

MR. WHEELER: So before we address timing, 23 Complainants would like to orally move to suspend the 24 procedural schedule until November 20th with respect to the 25 SHEnB and Cartessa Respondents.

MR. WHEELER: The only thing, Your Honor, is that 5 our understanding is that that motion is unopposed.

MR. NESTER: Your Honor, on the schedule, so we 24 have met and conferred -- JUDGE MCNAMARA: Pardon me.

Inventor: Jonaiu Na Signature: Date (Optional): Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form.

(Currently Amended) The apparatus of claim +41§., further comprising a drive shaft coupling the motor to the at least one needle wherein each of the plurality of restorably deflectable electrical contacts includes a depressible pin.

The apparatus 10, 320, 360,360,400,460 may be employed to apply cosmetics, medications and/or other actives directly to the skin and maintain their presence long-term while using LED or other actinic light to increase their effect on the cells and tissue in the body.

[0059] Chemicals 22A may include cosmetics, medications and other actives appropriate for dermalogical cells including AHA's (alpha hydroxy acid), natural oils, aloe vera compounds, collagen boosters, bt, chitosan, daeses, endorphins, photodynamic drugs (PDT) like (Photofrin or ALA), vitamins A, C E or others, kojic acid, retinols or other exfoliant, salicylic acid, anti oxidants or other youth boosters and anti aging cosmetic or medications, antiseptic, antibiotics, anti-cancer agents, aroma therapy agents, fruit and vegetable extracts, anti-inflammatory agents, pain relievers, hormones, depilatories, and others, but the scope of this invention is not limited to these alone but can include any helpful medication, herbal formula or active compound for the skin and/or other tissues.

As noted the DTA 900 SGC 911 RFSG 91 lA, NDMC 91 lB, and PSG 911 C may enable a user or clinician to select a variety of operational parameters to deliver a desired combination of electrical, light (photonic), and mechanical (needle) therapy to dermalogical tissue.